![]() |
|
|
Vol. 53, Issue 4, 623-629, April 1998
Department of Pharmacology and Toxicology and Department of Pathology, Michigan State University, East Lansing, Michigan 48824
| |
Summary |
|---|
|
|
|---|
The immune system has been identified as a sensitive target for the toxic effects produced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Furthermore, the B cell has been identified as a sensitive cellular target of TCDD by previous cell-type fractionation studies from this laboratory. The mechanism responsible for the immunotoxic effects produced by TCDD is unclear; however, many of the biological effects of TCDD are thought to be mediated by the aryl hydrocarbon receptor (AhR). Here, we describe two B cell lines that differ considerably in their expression of the AhR and in their sensitivity to TCDD. Our results demonstrated a marked expression of the AhR protein in the CH12.LX B cell line but not in the BCL-1 B cell line. Transcripts for the AhR were not detected by reverse transcriptase-polymerase chain reaction in the BCL-1 cells. The AhR nuclear translocator (ARNT) protein was highly expressed in both cell lines. In addition, the AhR and ARNT are functional in CH12.LX cells as demonstrated by TCDD-induced CYP1A1 induction. TCDD did not induce CYP1A1 in BCL-1 cells. Furthermore, TCDD treatment resulted in suppression of lipopolysaccharide (LPS)-induced IgM secretion in CH12.LX cells. Conversely, TCDD-induced inhibition of IgM secretion was not demonstrated in LPS-stimulated BCL-1 cells, implicating a role for the AhR in the inhibition of B cell effector function. LPS-induced differentiation of the CH12.LX cells also resulted in a marked induction of Ahr expression which was not induced in LPS-stimulated BCL-1 cells. These studies have implicated the AhR as a critical factor in TCDD-induced inhibition of IgM secretion and have demonstrated an induction of AhR gene and protein expression after B cell activation.
| |
Introduction |
|---|
|
|
|---|
HAHs
such as the polychlorinated
dibenzo-p-dioxins, dibenzofurans, and biphenyls are
persistent environmental toxins. TCDD has been considered the prototype
of HAHs because of its biological potency in experimental animals. A
plethora of biological effects have been observed in most animal models
after exposure to TCDD. Of these effects, which include a general
wasting syndrome, lymphoid involution (especially of the thymus),
hepatotoxicity, tumor promotion, and reproductive and developmental
toxicity (reviewed in Poland and Knutson, 1982
), immune suppression
seems to be one of the most sensitive consequences of TCDD exposure.
Effects of TCDD on immunocompetence have been well documented in
virtually every species studied and occur at doses that do not produce
obvious signs of toxicity (reviewed in Holsapple et al.,
1991
). Although TCDD-induced alterations of innate, cell-mediated, and
humoral immunity have been observed, a major cellular component of
humoral immunity, the B cell, has been identified by cell-type
fractionation studies as a highly sensitive cellular target for the
direct immunotoxic effects of TCDD (Dooley and Holsapple, 1988
).
The actual molecular mechanism responsible for the immunotoxic effects
produced by TCDD is unclear; however, many of the biological effects of
HAHs are thought to be mediated by the AhR (Rowlands and Gustafsson,
1997
). The AhR is a 95-110-kDa basic helix-loop-helix, ligand-dependent transcription factor (Burbach et al., 1992
)
which, in the absence of ligand, is primarily located in the cytoplasm and is complexed with heat shock protein-90 and other partially characterized proteins (Pollenz et al., 1994
; Enan and
Matsumura, 1996
; Ma and Whitlock, 1997
; Rowlands and Gustafsson, 1997
).
Ligand binding induces conformational changes in the AhR resulting in disassociation of the cytoplasmic complex and translocation of the
liganded AhR into the nucleus (Pollenz et al., 1994
;
Rowlands and Gustafsson, 1997
) where it forms a heterodimer with an
87-kDa basic helix-loop-helix protein called the ARNT protein (Reyes et al., 1992
). The AhR/ARNT complex can act as a
transcription factor by binding specific DNA sequences termed DREs in
the promoter regions of sensitive genes (Reyes et al., 1992
;
Rowlands and Gustafsson, 1997
). This mechanism has been primarily
elucidated and characterized by studying HAH-induced up-regulation of
drug metabolizing enzymes, such as CYP1A1, in hepatic tissue and
hepatic cell lines. The involvement of an AhR-mediated mechanism in the
toxicity, including immunotoxicity, induced by TCDD has not been
clearly established. In fact, the most TCDD-susceptible species in
terms of LD50, the guinea pig, does not show a
notable induction of liver microsomes with TCDD treatment (Kociba
et al., 1978
). In contrast, the least TCDD-susceptible
species in terms of LD50, the hamster, shows a
marked induction of liver microsomes with TCDD treatment (Matsumura, 1994
). In addition to metabolic enzymes, other genes, such as those
encoding plasminogen activator inhibitor-2, interleukin-1
, and
transforming growth factor-
and -
, have been shown to be up-regulated or down-regulated with TCDD treatment (Sutter et al., 1991
; Gaido et al., 1992
) but the mechanism of
this regulation is presently unknown.
Studies with congenic mice at the Ah locus and with Ah high responsive
and Ah low responsive mouse strains, as well as structure-activity relationship studies have generally supported a role for the AhR in the
immunotoxic effects produced by TCDD (Vecchi et al., 1983
; Davis and Safe, 1988
; Kerkvliet et al., 1990
). However, in
contrast to structure-activity relationships observed between AhR
binding and immunotoxicity, the low affinity AhR ligand,
2,7-dichlorodibenzo-p-dioxin, and TCDD produced comparable
inhibition of the T cell-dependent antibody forming cell response after
subchronic treatment of mice in vivo and after direct
addition to naive splenocytes in vitro (Holsapple et
al., 1986a
, 1986b
). The condition of TCDD exposure seems to be a
factor in segregation of the immunotoxicity with the AhR in that,
subchronic TCDD treatment produced a marked immunosuppression in DBA/2
(Ah low responsive), B6C3F1 (Ah high responsive), and congenic mice
encoding for an AhR with low affinity for TCDD (Morris et
al., 1992
; Holsapple et al., 1986a
). These results
indicate a loss of the resistance originally seen in DBA/2 and congenic mice acutely treated with TCDD (Vecchi et al., 1983
;
Kerkvliet et al., 1990
). In light of the above observations,
it is unclear what role the AhR plays in mediating the toxicity of
TCDD.
The objective of the current studies was to develop a cell line model system for the purpose of elucidating the role of the AhR in the well documented alteration of B cell function by TCDD. In this report, we describe two B cell lines that differ markedly in their expression of the AhR as well as in their sensitivity to TCDD. Furthermore, studies with these cell lines have identified the AhR as a critical factor in TCDD-induced inhibition of IgM secretion and have demonstrated an induction of AhR gene and protein expression after B cell activation with a differentiating signal.
| |
Materials and Methods |
|---|
|
|
|---|
Cell lines.
The CH12.LX B cell line derived from the murine
CH12 B cell lymphoma, which arose in
B10.H-2aH-4bp/Wts mice
(B10.A × B10.129), has been previously characterized (Bishop and
Haughton, 1986
) and was a generous gift from Dr. Geoffrey Haughton
(University of North Carolina, Chapel Hill, NC). The BCL-1 B cell line
was derived from a murine B cell lymphoma that spontaneously arose in a
BALB/c mouse (Slavin and Strober, 1978
). This cell line has been
previously characterized (Gronowicz et al., 1980
) and was
generously provided by Dr. Kathryn H. Brooks (Michigan State
University, East Lansing, MI). CH12.LX and BCL-1 cell lines were grown
in RPMI-1640 (Gibco BRL, Grand Island, NY) supplemented with
heat-inactivated 10% bovine calf serum (Hyclone, Logan, UT), 13.5 mM HEPES, 23.8 mM sodium bicarbonate, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM
L-glutamine, 0.1 mM nonessential amino acids,
1.0 mM sodium pyruvate, and 50 µM
-mercaptoethanol. The mouse hepatoma cell line, Hepa 1c1c7, was
generously provided to our laboratory by Dr. Michael S. Denison
(University of California, Davis, CA). Hepa 1c1c7 cells were cultured
in
-minimal essential media (Gibco BRL, Grand Island, NY)
supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 10% bovine calf serum. All
cells were maintained at 37° in an atmosphere of 5%
CO2.
Western blot analysis.
Western blot analysis was performed
on whole cell lysates from CH12.LX, BCL-1, and Hepa 1c1c7 cells. Cell
lysates were prepared in buffer A (25 mM HEPES, 2 mM EDTA, 1 mM dithiothreitol, 10% glycerol and
20 mM sodium molybdate), homogenized, and centrifuged at
105,000 × g for 1 hr at 4°. Protein concentrations
were determined by the Bradford protein assay (Sigma, St. Louis, MO).
Cell lysate proteins were resolved by denaturing SDS-PAGE with 7.5%
polyacrylamide (National Diagnostics, Atlanta, GA). The electrophoresed
proteins were transferred to nitrocellulose (Amersham, Arlington
Heights, IL). Protein blots were blocked in BLOTTO buffer (5% low-fat
dry milk in 0.1% Tween 20, Tris-buffered saline) for 1-2 hr at 22°. Primary antibodies to the AhR (17-10B) and ARNT protein (20-9B), previously characterized by Pollenz et al. (1994)
, were a
generous gift of Dr. Richard S. Pollenz (Medical University of South
Carolina, Charleston, SC). Immunochemical staining was performed as
previously described (Williams et al., 1996
) with the
following exception. The anti-AhR antibody and the anti-ARNT antibody
were diluted to 1 µg/ml in antibody dilution buffer (0.1% Ficoll,
0.1% polyvinylpyrrolidone, 0.05% gelatin, 0.1% Nonidet P-40, and
0.5% bovine serum albumin in borate-buffered saline). Detection was
performed using the electrochemiluminescence method (Amersham).
Absorbance for the protein of interest was measured by densitometry
using a model 700 imaging system (Bio-Rad, Hercules, CA).
Quantitative RT-PCR.
Quantitative RT-PCR was performed as
previously described (Williams et al., 1996
) with several
modifications. Briefly, total RNA from each sample was isolated using
Tri Reagent (Sigma). RNA samples were first analyzed for DNA
contamination by PCR analysis without RT. RNA samples containing DNA
were incubated with RNase-free DNase as previously described (Williams
et al., 1996
). Total DNA-free RNA (100 ng) and internal
standard (recombinant RNA) were reverse transcribed simultaneously in
the same reaction tube. AhR and ARNT primers were
as previously described (Williams et al., 1996
). Final
reaction concentrations for the AhR PCR reaction were 4 mM MgCl2 and 2.5 units of
Taq DNA polymerase (Promega, Madison, WI). Samples were
cycled 35 times with each cycle consisting of 94° for 15 sec, 59°
for 30 sec, and 72° for 45 sec. The ARNT PCR was performed
as described for the AhR PCR, except the samples were cycled
32 times. PCR products were visualized by ethidium bromide staining and
quantitation was performed by assessing the absorbance for both the
target and internal standard DNA using a Gel Doc 1000 video imaging
system (Bio-Rad). The number of transcripts were calculated from a
standard curve generated from the density ratio between the gene of
interest and a specific internal standard concentration. Primers for
the CYP1A1 gene were a generous gift of Dr. Dale Morris (J. D. Searle, Skokie, IL). The CYP1A1 PCR was performed as described
above for the AhR PCR, except the annealing temperature was
56° and the samples were cycled 32 times.
ELISA. Supernatants were harvested from naive or LPS (30 µg/ml)-stimulated CH12.LX or BCL-1 cells after a 72-hr incubation at 37° in 5% CO2 and were analyzed for IgM by sandwich ELISA. Briefly, 100 µl of supernatant or standard (mouse IgM, Sigma) were added to wells of a 96-well microtiter plate coated with anti-mouse immunoglobulin capture antibody (Boehringer Mannheim, Indianapolis, IN), and then incubated at 37° for 1.5 hr. After the incubation period, the plate was washed with 0.05% Tween-20 phosphate-buffered saline and H20, followed by addition of a horseradish peroxidase anti-mouse IgM detection antibody (Sigma) and another incubation at 37° for 1.5 hr. Unbound detection antibody was washed from the plate after the incubation period with 0.05% Tween 20, phosphate-buffered saline, and H2O. 2,2'-azinobis(3-ethylbenz thiazoline-sulfonic acid) ABTS substrate (Boehringer Mannheim) was added and colorimetric detection was performed over a 1 hr period using an EL808 automated microplate reader with a 405-nm filter (Bio-Tek, Winooski, VT). The DeltaSoft 3 computer analysis program (BioMetallics, Princeton, NJ) calculated the concentration of IgM in each sample from a standard curve generated from the absorbance readings of known IgM concentrations.
Statistical analysis of data. The mean ± standard error was determined for each treatment group of a given experiment. When significant differences occurred, treatment groups were compared with the vehicle controls using a Dunnett's two-tailed t test.
| |
Results |
|---|
|
|
|---|
AhR and ARNT expression in CH12.LX and BCL-1 B cell lines. Western analysis for AhR and ARNT was performed using whole cell lysates from the CH12.LX and BCL-1 B cell lines. Interestingly, an approximately 95-kDa AhR was markedly expressed in CH12.LX cells but was not detected in BCL-1 cells (Fig. 1A). The 87-kDa ARNT protein was well expressed in both B cell lines (Fig. 1B). To confirm a lack of AhR expression in BCL-1 cells, total RNA isolated from BCL-1 cells was analyzed by qualitative RT-PCR analysis, a more sensitive technique than Western analysis. In agreement with the above results, AhR transcripts were not detected in BCL-1 RNA (Fig. 2A). Quantitative RT-PCR analysis of basal AhR and ARNT transcripts demonstrated a much greater expression of ARNT in CH12.LX cells as compared with AhR (Fig. 2B). In addition, similar levels of ARNT transcripts were detected in BCL-1 cells as compared with CH12.LX cells (Fig. 2B).
|
|
AhR and ARNT regulate gene transcription in the CH12.LX B cell line. "Functionality" of AhR and ARNT was evaluated in CH12.LX cells by the ability of TCDD to induce CYP1A1 expression. Unlike the electrophoretic mobility sift assay, which is only an indicator of DRE binding, TCDD-induced up-regulation of Cyp1a1 is an indicator of transcriptional regulation mediated by DRE binding, and thus is a more comprehensive indicator of AhR/ARNT function. Evaluation of Cyp1a1 gene expression by quantitative RT-PCR demonstrated a marked and rapid increase in CYP1A1 transcripts after TCDD treatment. TCDD-induced CYP1A1 expression occurred as early as 2 hr and was maximal by 8 hr, remaining elevated throughout the time course (Fig. 3). Induction of Cyp1a1 in CH12.LX cells is also dose-dependent. An 8-hr treatment of TCDD at concentrations of 0.003, 0.03, 0.3, and 3.0 nM induced CYP1A1 expression 14-, 38-, 44- and 120-fold, respectively, above the vehicle control. BCL-1 cells were also analyzed for Cyp1a1 inducibility. As predicted because of the lack of AhR expression, CYP1A1 transcripts were not detected by qualitative RT-PCR analysis in TCDD-treated BCL-1 cells (Fig. 4).
|
|
TCDD alters immune function in CH12.LX B cells but not in
AhR-deficient BCL-1 B cells.
To assess the sensitivity of CH12.LX
cells and BCL-1 cells to TCDD, LPS-induced IgM secretion was measured
by ELISA. In primary B cells TCDD has been previously shown to suppress
IgM secretory responses to the polyclonal B cell-activator LPS (Dooley
and Holsapple, 1988
) and to soluble anti-IgM (Karras and Holsapple,
1994
). LPS can induce CH12.LX and BCL-1 cells to secrete IgM and
treatment of CH12.LX cells with TCDD resulted in a marked inhibition of LPS-induced IgM secretion at doses as low as 0.03 nM TCDD
(Fig. 5). In contrast, LPS-induced IgM
secretion in AhR-deficient BCL-1 cells was not inhibited at
concentrations as high as 3.0 nM TCDD (Fig.
6).
|
|
Differential expression of AhR in LPS-differentiated CH12.LX B cells. The effect of LPS-induced differentiation of the CH12.LX and BCL-1 cells on AhR gene expression was evaluated by RT-PCR. A marked up-regulation of AhR gene expression occurred by 4 hr in LPS-activated CH12.LX cells (Fig. 7). In contrast, LPS-induced activation of BCL-1 cells did not result in expression of the AhR gene (Fig. 8). Consistent with AhR gene expression, Western analysis for the AhR protein in LPS-activated CH12.LX cells demonstrated an increase in protein expression by 8 hr (Fig. 9). In addition, LPS treatment did not alter basal ARNT mRNA or protein expression (data not shown).
|
|
|
| |
Discussion |
|---|
|
|
|---|
We have identified two B cell lines that differ notably in their
expression of the AhR as well as in their sensitivity to TCDD. The
CH12.LX B cell line markedly expresses both the AhR and ARNT protein as
determined by Western and RT-PCR analysis; whereas, the BCL-1 B cell
line expresses only the ARNT protein and lacks expression of the AhR at
the mRNA level. Although a basis for the loss of AhR
expression in BCL-1 cells is unknown, it is noteworthy that the BCL-1
cell line is derived from an Ah high responsive BALB/c mouse strain,
which has been characterized as expressing an AhR allele that
encodes for an AhR with high affinity for TCDD (Poland and Glover,
1990
). Further characterization of the AhR in the CH12.LX cells has
verified a close similarity with results from studies conducted in
primary lymphocytes. Specifically, the basal mRNA expression of
AhR and ARNT in primary lymphocytes was very
similar to that detected in CH12.LX cells (Williams et al.,
1996
). In addition, both primary lymphocytes and CH12.LX cells
exhibited a greater expression of ARNT transcripts as
compared with AhR transcripts (Williams et al.,
1996
). This difference in expression has been detected in a variety of
tissues and has led to the speculation that ARNT has other biological
roles (Carver et al., 1994
). As previously demonstrated in
primary lymphocytes (Williams et al., 1996
; Crawford
et al., 1997
), the AhR and ARNT protein were shown to be
"functional" in the CH12.LX cells by their ability to regulate
Cyp1a1 transcription.
As stated earlier, inhibition of IgM secretion from primary B cells is
a sensitive biological consequence of TCDD exposure (Holsapple et
al., 1991
); however, the involvement of the AhR in mediating this
effect is unclear. In addition to the previously mentioned studies
involving acute 2,7-dichlorodibenzo-p-dioxin treatment and
subchronic TCDD treatment in which immunotoxicity did not segregate
with the AhR (Holsapple et al., 1986a
, 1986b
; Morris
et al., 1992
), several other investigators have demonstrated TCDD-mediated events not dependent on a functional AhR. These include
induction of junB and c-fos (Puga et
al., 1992
), induction of protein kinases (Bombick et
al., 1988
), PLC activation (Beebe et al., 1990
), and
Ca2+ influx (Puga et al., 1992
).
Induction of immediate early genes such as junB and
c-fos are known to be involved in regulation of cellular
proliferation and differentiation. In addition, increased protein
phosphorylation that did not segregate with the AhR (Snyder et
al., 1993
) and an increase in Ca2+ influx
(Karras et al., 1996
) have been identified in primary B
cells. The increase in Ca2+ influx may also be
AhR-independent as demonstrated by Puga et al. (1992)
in
hepatoma cells. Moreover, increased protein phosphorylation (Snyder
et al., 1993
) and Ca2+ influx (Karras
et al., 1996
) were implicated in TCDD-induced suppression of
the antibody response, further questioning the role of the AhR in
suppression of antibody secretion.
Like primary B cells, CH12.LX cells respond to an LPS-differentiating signal with a significant increase in IgM secretion. Although lacking the AhR, BCL-1 cells are viable and are also capable of differentiating into antibody-secreting cells. Therefore, BCL-1 cells respond similarly to an LPS-differentiating signal as compared with CH12.LX cells, which suggests that these cells have all of the necessary signaling components for B cell activation. We have found that TCDD treatment of CH12.LX cells results in a sensitive and marked inhibition of IgM secretion similar to that seen in primary B cells; however, LPS-induced IgM secretion from the AhR-deficient BCL-1 cells is not sensitive to inhibition by TCDD. These results are the first to directly implicate a role for the AhR in mediating a TCDD-induced alteration of B cell function. It is important to emphasize that, although our conclusion is slightly tempered because of the fact that our results are obtained from cell lines originating from two different mouse strains, we believe that the cell lines are in fact quite comparable. As stated above, both lines are derived from Ah high responsive mouse strains as evidenced by sensitivity to TCDD and high affinity binding of TCDD to the AhR. Equally important, both cell lines respond similarly to an LPS-differentiating signal (i.e., secrete IgM).
A differential regulation of basal AhR gene expression was
demonstrated in cells of different lineages using deletion constructs of the AhR 5'-flanking region (FitzGerald et al.,
1996
). The authors concluded that this variation in regulation of
AhR expression may provide the basis for differences in the
sensitivity of various tissues to TCDD (FitzGerald et al.,
1996
). Seeming to be in contrast with the above conclusion, leukocytes
are very sensitive to TCDD, yet they express relatively low levels of
AhR as compared with other target organs, such as the liver (Williams
et al., 1996
). However, an up-regulation of AhR gene and
protein expression was recently demonstrated in PMA/Io-stimulated
primary leukocytes revealing a possible explanation for the sensitivity
of these cells to TCDD (Crawford et al., 1997
). In agreement
with these results, an up-regulation of AhR gene and protein expression
was detected in LPS-activated CH12.LX cells in the absence of TCDD. Taken together these results demonstrate an induction of the AhR upon
lymphocyte activation and suggest a role for the AhR in cellular proliferation and/or differentiation. An additional consequence of AhR
up-regulation may be an increased nuclear translocation and binding of
ligand-activated AhR to DREs located in promoter regions of genes
sensitive to TCDD. Masten and Shiverick (1995)
recently identified
negative regulation by TCDD of a B cell-specific gene. This seemed to
be mediated by an AhR/DRE mechanism through a competition between the B
cell-specific transcription factor, BSAP, and the AhR nuclear complex
for binding to DNA that contained a DRE motif within the binding site
for BSAP (Masten and Shiverick, 1995
). It is likely that other genes
involved in cellular proliferation and differentiation of B cells may
also contain DREs within their promoter regions. If so, the activated
AhR nuclear complex may directly interfere with DNA binding of lineage
specific transcription factors, such as BSAP, or simply modulate gene
expression by binding DREs. In addition to activated leukocytes, an
up-regulation of AhR gene expression has been observed during
monocyte differentiation (Hayashi et al., 1995
) and
keratinocyte differentiation (Wanner et al., 1995
). The AhR
has also been implicated in cell cycle regulation of Hepa 1c1c7 cells.
Specifically, cells deficient in AhR have a longer doubling time then
wild-type cells expressing the AhR. Introduction of antisense AhR cDNA
into wild-type cells results in a longer doubling time resembling that
of the AhR-deficient cells (Ma and Whitlock, 1996
).
Until now, we have lacked an appropriate model to study the mechanisms
involved in one of the most sensitive effects of TCDD exposure,
alteration of B cell function. A majority of the work characterizing
the AhR has been performed using the hepatic cell line model, Hepa
1c1c7, and various clones of this cell line that are defective in the
AhR or ARNT protein (Miller et al., 1983
). However, B cells
are unique among the cellular targets of TCDD in that these cells
require cellular activation before mediating their effector functions.
Because the AhR may have a significant role in cellular proliferation
and/or differentiation as discussed earlier, the B cell may represent
an important model for studying the role of the AhR in these processes.
| |
Acknowledgments |
|---|
We thank Dr. Richard S. Pollenz for providing the anti-AhR and ARNT antibodies, Dr. Kathryn H. Brooks for the BCL-1 cells and Dr. Geoffrey Haughton for his gift of the CH12.LX cells.
| |
Footnotes |
|---|
Received October 6, 1997; Accepted December 22, 1997
1 Current affiliation: Dow Chemical Company, Midland, MI 48674.
This work was supported in part by funds from National Institute of Environmental Health Sciences Grant ES02520.
Send reprint requests to: Dr. Norbert E. Kaminski, Dept. of Pharmacology & Toxicology, B330 Life Sciences Bldg., Michigan State University, East Lansing, MI 48824.
| |
Abbreviations |
|---|
HAH, halogenated aromatic hydrocarbon; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; AhR, aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; DRE, dioxin-responsive enhancer; LD50, 50% of lethal dose; RT, reverse transcriptase; PCR, polymerase chain reaction; LPS, lipopolysaccharide; ELISA, enzyme-linked immunosorbent assay; BSAP, B cell-specific activator protein; PAGE, polyacrylamide gel electrophoresis; DMSO, dimethylsulfoxide; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
| |
References |
|---|
|
|
|---|
and -
2 expression in a human keratinocyte cell line involves both transcriptional and post-transcriptional control.
J Biol Chem
267:
24591-24595
.
Science (Washington DC)
254:
415-418This article has been cited by other articles:
![]() |
D. Schneider, M. A. Manzan, R. B. Crawford, W. Chen, and N. E. Kaminski 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Impairment of B Cell Differentiation Involves Dysregulation of Paired Box 5 (Pax5) Isoform, Pax5a J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 463 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Boverhof, E. Tam, A. S. Harney, R. B. Crawford, N. E. Kaminski, and T. R. Zacharewski 2,3,7,8-Tetrachlorodibenzo-p-dioxin Induces Suppressor of Cytokine Signaling 2 in Murine B Cells Mol. Pharmacol., December 1, 2004; 66(6): 1662 - 1670. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. W. Sulentic, W. Zhang, Y. J. Na, and N. E. Kaminski 2,3,7,8-Tetrachlorodibenzo-p-dioxin, an Exogenous Modulator of the 3'{alpha} Immunoglobulin Heavy Chain Enhancer in the CH12.LX Mouse Cell Line J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 71 - 78. [Abstract] [Full Text] |
||||
![]() |
B. S. Yoo, D. R. Boverhof, D. Shnaider, R. B. Crawford, T. R. Zacharewski, and N. E. Kaminski 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Alters the Regulation of Pax5 in Lipopolysaccharide-Activated B Cells Toxicol. Sci., February 1, 2004; 77(2): 272 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shibazaki, T. Takeuchi, S. Ahmed, and H. Kikuchi Suppression by p38 MAP Kinase Inhibitors (Pyridinyl Imidazole Compounds) of Ah Receptor Target Gene Activation by 2,3,7,8-Tetrachlorodibenzo-p-dioxin and the Possible Mechanism J. Biol. Chem., January 30, 2004; 279(5): 3869 - 3876. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Crawford, C. E. W. Sulentic, B. S. Yoo, and N. E. Kaminski 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Alters the Regulation and Posttranslational Modification of p27kip1 in Lipopolysaccharide-Activated B Cells Toxicol. Sci., October 1, 2003; 75(2): 333 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Martinez, C. A. Afshari, P. R. Bushel, A. Masuda, T. Takahashi, and N. J. Walker Differential Toxicogenomic Responses to 2,3,7,8-Tetrachlorodibenzo-p-dioxin in Malignant and Nonmalignant Human Airway Epithelial Cells Toxicol. Sci., October 1, 2002; 69(2): 409 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Dudley, M. M. Peden-Adams, J. EuDaly, R. S. Pollenz, and D. E. Keil An Aryl Hydrocarbon Receptor Independent Mechanism of JP-8 Jet Fuel Immunotoxicity in Ah-Responsive and Ah-Nonresponsive Mice Toxicol. Sci., February 1, 2001; 59(2): 251 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. W. Sulentic, M. P. Holsapple, and N. E. Kaminski Putative Link between Transcriptional Regulation of IgM Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin and the Aryl Hydrocarbon Receptor/Dioxin-Responsive Enhancer Signaling Pathway J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 705 - 716. [Abstract] [Full Text] |
||||
![]() |
T. S. Thurmond and T. A. Gasiewicz A Single Dose of 2,3,7,8-Tetrachlorodibenzo-p-dioxin Produces a Time- and Dose-Dependent Alteration in the Murine Bone Marrow B-Lymphocyte Maturation Profile Toxicol. Sci., November 1, 2000; 58(1): 88 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Shepherd, E. A. Dearstyne, and N. I. Kerkvliet The Effects of TCDD on the Activation of Ovalbumin (OVA)-Specific DO11.10 Transgenic CD4+ T cells in Adoptively Transferred Mice Toxicol. Sci., August 1, 2000; 56(2): 340 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Cunningham, A. Dunne, P. Sabido, D. Lightner, and T. J. Mantle Studies on the Specificity of the Tetrapyrrole Substrate for Human Biliverdin-IXalpha Reductase and Biliverdin-IXbeta Reductase. STRUCTURE-ACTIVITY RELATIONSHIPS DEFINE MODELS FOR BOTH ACTIVE SITES J. Biol. Chem., June 16, 2000; 275(25): 19009 - 19017. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||